Papulosquamous disorders: biologics in psoriasis: practice question

A Dermatology question in the style of the NEET PG paper. Answer it first, then read why the right option is right and why each of the others is wrong.

Try it

Dermatology · Papulosquamous disorders: biologics in psoriasis

Sample item

Secukinumab, used for moderate to severe plaque psoriasis, acts against which target?

Original practice item, not a recalled exam question. Nothing here is recorded.

The answer and the reasoning

A. Interleukin-17A

Secukinumab is a monoclonal antibody that neutralises IL-17A, a key cytokine of the Th17 pathway in psoriasis. Screening for tuberculosis and hepatitis is needed before biologic therapy.

Option by option

  • A. Interleukin-17A (correct)

    Correct. Secukinumab neutralises IL-17A.

  • B. CD20

    Rituximab targets CD20 and is used in pemphigus.

  • C. Interleukin-4 receptor alpha

    Dupilumab blocks IL-4 receptor alpha for atopic dermatitis.

  • D. Tumour necrosis factor alpha

    Anti-TNF agents include infliximab, adalimumab and etanercept.

Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.

More Dermatology questions

Questions about this Dermatology question

What is the answer to this Dermatology question?

The best answer is A, Interleukin-17A. Secukinumab is a monoclonal antibody that neutralises IL-17A, a key cytokine of the Th17 pathway in psoriasis.

Why is "CD20" not the answer?

Rituximab targets CD20 and is used in pemphigus.

Why is "Interleukin-4 receptor alpha" not the answer?

Dupilumab blocks IL-4 receptor alpha for atopic dermatitis.

Why is "Tumour necrosis factor alpha" not the answer?

Anti-TNF agents include infliximab, adalimumab and etanercept.

What concept does this question test?

It tests Papulosquamous disorders: biologics in psoriasis in Dermatology. Screening for tuberculosis and hepatitis is needed before biologic therapy.

How hard is this question?

We tag it as an application question: it asks you to use a fact on a patient or a finding. The tag is our own editorial judgement, not an official difficulty rating, so read the reason for every option, not only the answer.

How should I study Papulosquamous disorders: biologics in psoriasis?

Learn each condition by its primary lesion, site and signature sign. Then use the flashcards and the other Dermatology questions on this site to test what stuck.

Is this a real NEET PG question?

No. It is an original practice item (editorial status: sample, version 1). NextPrep does not publish recalled or leaked questions, and independent faculty review of this item has not been completed yet, so confirm important facts in a standard textbook.